Exploring the therapeutic potential of Beta-3 adrenergic agonists in overactive bladder: A comparative analysis of monotherapy versus combination therapy strategies. (PubMed, Wiad Lek) - Sep 17, 2026 - " Beta-3 agonist as monotherapy is a potent, multimodality first-line therapy with strong influence of severe disease. Each of combinatory treatments show characteristic effect on phenotype-specific increase in bladder capacity. Mirabegron flaoxate could be considered for detrusor hypertrophy and combination of mirabegron Solifenacin would stimulate voiding facilitate. These proof of concept data justify PPTP based on objective biomarkers such as BWT and PVR to select combination therapy in what is another small step in our journey towards precision medicine for OAB."
Clinical • Journal • Monotherapy • Observational data • Overactive Bladder
|
|
Bushra A Lafta; Firas S Attar; Jawad K Hasan; Noor Abdullah; Safaa A Mohssin; Shaymaa Fadhil Abbas
|